Antengene Wins Malaysian sNDA Approval Expanding XPOVIO Selinexor Indications to Relapsed or Refractory DLBCL
Wednesday, December 17, 2025
Antengene Corporation Limited has announced that Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) has approved a supplemental New Drug Application (sNDA) for XPOVIO (selinexor), extending the medicine’s use to adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior systemic therapies and are ineligible for autologous stem cell transplant.[1] This new hematology oncology indication significantly broadens the clinical and commercial footprint of XPOVIO in the Malaysian market, where the product had previously been approved only for specific multiple myeloma settings. For B2B pharma stakeholders across Asia, this expansion highlights both the accelerating pace of advanced oncology approvals in Southeast Asia and the growing strategic importance of Malaysia within regional market access plans.
Before this decision, XPOVIO was already approved in Malaysia in two multiple myeloma (MM) indications: in combination with bortezomib and dexamethasone for adult patients who had received at least one prior therapy, and in combination with dexamethasone for heavily pretreated adults whose disease is refractory to multiple proteasome inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody.[1] With the DLBCL expansion, Malaysian hematologists now have an orally administered, first-in-class selective inhibitor of nuclear export (XPO1) to manage a highly challenging, late-line lymphoma population. From a business and market access standpoint, Antengene now commands three approved indications for XPOVIO in Malaysia across two major hematology segments, improving the asset’s utilization potential and strengthening physician familiarity with the brand.
XPOVIO is described as the world’s first approved, orally available, selective XPO1 inhibitor, and it has already secured regulatory approvals in ten countries and regions across the Asia Pacific, including mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia.[1] In five of these markets—mainland China, Taiwan, Australia, South Korea, and Singapore—the product has been integrated into national insurance or reimbursement schemes, establishing an important precedent for eventual payer negotiations in additional Asian jurisdictions. The Malaysian DLBCL approval therefore not only has direct local impact but also reinforces the broader APAC narrative that regionally developed or co-developed oncology innovations can achieve wide geographic penetration accompanied by structured reimbursement pathways.
For regulators, payers, and hospital decision makers in Asia, this development illustrates how targeted therapies with well-differentiated mechanisms of action can be rapidly life-cycle managed through indication expansions that leverage existing safety, efficacy, and pharmacoeconomic data. DLBCL remains one of the most common non-Hodgkin lymphomas worldwide, and outcomes in heavily pretreated, transplant-ineligible patients are generally poor, driving demand for additional therapeutic options. The Malaysian NPRA’s willingness to greenlight a supplemental filing in this population signals increasing regulatory comfort with novel mechanisms in hematologic malignancies, provided that sponsors can deliver robust clinical evidence and clear benefit–risk profiles. This, in turn, influences investment planning for other regional and global biotech companies evaluating where to prioritize Phase 2 or Phase 3 trials and subsequent submissions.
From an R&D pipeline perspective, Antengene has positioned itself as an Asia-rooted, R&D-driven biotech with a mix of in-licensed and internally discovered assets.[1] The company reports having obtained 32 Investigational New Drug (IND) approvals across the United States and Asia, and it has submitted New Drug Applications (NDAs) in 11 Asia Pacific markets. Its pipeline includes programs such as ATG-022 (a CLDN18.2 antibody–drug conjugate), ATG-037 (an oral CD73 inhibitor), ATG-101 (a PD-L1 × 4-1BB bispecific antibody), ATG-031 (a CD24-targeting macrophage activator), and ATG-042 (an oral PRMT5-MTA inhibitor).[1] The successful expansion of XPOVIO’s label in Malaysia can be viewed as a proof point that Antengene can navigate multi-jurisdictional regulatory frameworks and leverage its commercial infrastructure to optimize the value of its lead oncology asset while laying the groundwork for future launches.
For executives and strategists in the regional pharma ecosystem, the Malaysian DLBCL approval underscores the significance of a multi-country, multi-indication strategy when advancing oncology therapies in Asia. The ability to align regulatory submissions across markets like China, ASEAN members, South Korea, and Australia not only maximizes the return on clinical development investment but also supports cross-border evidence generation and real-world data collection. Payers and health technology assessment (HTA) bodies in emerging Asian markets increasingly look to peer markets for benchmarking, and an oncology drug that has already demonstrated acceptance in several advanced healthcare systems often faces lower barriers to formulary inclusion. This dynamic may accelerate subsequent pricing and reimbursement discussions for XPOVIO in Malaysia, particularly if local health economic models show value in high-need lymphoma populations.
Operationally, the expansion of indications in a country such as Malaysia can drive incremental demand for supporting diagnostic, pharmacy, and distribution infrastructure. Hospital pharmacies and oncology centers will need to adapt their treatment protocols, stock management, and patient monitoring frameworks to incorporate XPOVIO for DLBCL patients who qualify under the new criteria. Meanwhile, Antengene’s field teams across medical affairs, market access, and commercial functions will likely intensify engagement with key opinion leaders, professional societies, and payers to communicate the clinical profile of selinexor and clarify its positioning relative to existing regimens and emerging competitors. These activities contribute to a more robust innovation ecosystem in Southeast Asia and may influence other biotech and pharmaceutical firms considering similar launch sequences.
At the strategic portfolio level, the DLBCL label extension in Malaysia enhances XPOVIO’s differentiation as a hematology franchise product rather than a single-indication multiple myeloma therapy. This shift is critical from a lifecycle management and valuation standpoint: multi-indication oncology brands typically command stronger long-term revenue trajectories, particularly when supported by ongoing clinical trials exploring combination regimens and earlier lines of therapy. For board members, investors, and licensing partners, the Malaysian approval could therefore be interpreted as incremental de-risking of the asset in Asia Pacific, with positive implications for partnering discussions, co-commercialization negotiations, and potential out-licensing deals targeting specific territories.
In the wider context of Asia’s biopharmaceutical development, Antengene’s progress with XPOVIO reflects a broader transition in the region from generics-dominated portfolios toward innovation-led pipelines focused on first-in-class and best-in-class products. Countries such as Malaysia, with evolving regulatory capacity and growing oncology burden, are becoming test beds for agile access models and collaborative engagement between regulators, payers, and innovative biotechs. The XPOVIO DLBCL approval will likely be monitored by other ASEAN regulators, as well as multinational companies planning to position novel targeted therapies in comparable patient segments. For Asia-focused B2B pharma stakeholders—from CDMOs and CROs to digital health providers and data analytics firms—this development signals continued demand for sophisticated support services that can help innovative therapies navigate the complex intersection of clinical evidence, regulatory expectations, and payer requirements across multiple Asian jurisdictions.
Looking ahead, Antengene has indicated that it expects XPOVIO to receive public insurance coverage in additional Asia Pacific markets beyond the five where it is already reimbursed.[1] While specific timelines and payer negotiations remain confidential, each new indication and jurisdiction strengthens the data and market access dossier that the company can present to health authorities. For Malaysian healthcare regulators and hospital administrators, the key operational questions will center on how to best integrate selinexor into treatment algorithms for DLBCL, evaluate patient selection criteria, manage side-effect profiles in real-world practice, and assess the budget impact within constrained oncology funding envelopes. Answers to these questions will shape not only the commercial performance of XPOVIO in Malaysia but also the evolving standards of care for relapsed or refractory DLBCL across the broader Asia Pacific region.
